Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIT 1: Granexin gel for diabetic foot ulcer
2018-001725-75Phase 3Terminated
- Sponsor
- Xequel Bio
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing Granexin gel + standard-of-care with Vehicle gel + standard-of-care (2 arms). Started Jan 2019; status: terminated.
02
Drugs
aCT1
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2018-001725-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001725-75.